TOP TRENDING

The "potent" experimental Covid-19 drug administered to Trump is set to be launched in 30 UK hospitals


The "potent" experimental Covid-19 drug administered to Trump has already been used on four hundred British patients and is due to be launched in 30 British hospitals this week

  • British patients first received REGN-COV2 from a New York company last week
  • Peter Horby, a professor at Oxford University, said UK studies had "promising" results
  • Horby said a single dose could provide "extended protection" for over a month.
  • The treatment will roll out in an additional 30 to 40 hospitals in the UK next week

The experimental coronavirus drug that Donald Trump will be given is due to be launched in 30 or 40 UK hospitals this week as it is rated "very effective" by UK scientists.

Peter Horby, a professor at Oxford University, said UK patients received REGN-COV2 from Regeneron Pharmaceuticals last weekend as part of the Oxford University National Recovery Study.

The US President received artificial antibody treatment in the White House on Friday after he was diagnosed with Covid-19.

Professor Horby, who specializes in emerging infectious diseases at Oxford and is co-chief investigator of the recovery study, said "about three hospitals in the north" were the first to start using the drug, adding that it was on "Another" will expand to 30 to 40 hospitals in the UK next week.

British Professor of Emerging Infectious Diseases Peter Horby during a digital press conference at No. 10 Downing Street in London, Britain, June 16, 2020

Prof. Horby spoke of the drug as "very promising" on Saturday's Today program on BBC Radio 4.

He said, “The class of drugs, these man-made antibodies, have been around for a while and they are used extensively in inflammatory diseases and cancers. They're pretty safe and well understood, and so is technology. I think we have faith in something.

“This particular drug has likely been given to four or five hundred patients, light or heavy patients in various studies, and so far there have been no safety signals of concern.

'In the laboratory, in cell cultures, it has very strong effects against the virus, and studies have been carried out on artificial animals where it also shows benefits.

"Of the drugs available, it is probably one of the most promising."

Professor Horby said a single dose of treatment provides "extended protection" for "one month to six weeks," which makes it "very attractive to the elderly".

In UK studies, the drug was first tested on genetically engineered mice before being tested on 275 people, 40 percent of whom were classified as obese. Image from a picture agency

In UK studies, the drug was first tested on genetically engineered mice before being tested on 275 people, 40 percent of whom were classified as obese. Image from a picture agency

The antibody cocktail binds to a protein on the surface of the virus, preventing it from attaching to cells and replicating, while the immune system can attack the virus.

REGN-COV2 is made up of two monoclonal antibodies (REGN10933 and REGN10987) that were made by humans to act like human antibodies in the immune system.

It was first tested on mice that were genetically engineered to have a human immune system before being tested on 275 people, 40 percent of whom were classified as obese.

Details of the UK study were announced on September 14 when Prof. Horby said he expected it would also be tested on "at least 2,000" randomly assigned patients in 174 hospitals.

President Donald Trump drives past trailers outside the Walter Reed National Military Medical Center in Maryland, where he was treated with REGN-COV2. Sunday 4th October

President Donald Trump drives past trailers outside the Walter Reed National Military Medical Center in Maryland, where he was treated with REGN-COV2. Sunday 4th October

Nick Cammack, who heads Covid-19 therapeutics for Wellcome, described monoclonal antibodies as "the most exciting" treatments for Covid-19 because they are specific to the disease, but also "traditionally the most expensive".

He said, “Large randomized controlled trials like Recovery give us the best understanding of whether drugs like REGN-COV2 are safe and effective for Covid-19, but we need to ensure that any successful treatment is available to anyone who needs it worldwide . & # 39;

Regeneron has partnered with pharmaceutical giant Roche to increase the global supply of REGN-COV2 if it proves effective.

Mr Trump received the drug along with remdesivir, an antiviral treatment that has been shown to help some coronavirus patients recover faster, as well as zinc, vitamin D, an antacid called famotidine, melatonin, and aspirin.

advertising

(tagsToTranslate) Dailymail (t) Nachrichten (t) Coronavirus (t) Donald Trump